Agenus' botensilimab in combination with balstilimab shows 33% durable responses in ovarian cancer

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced results from a cohort of 24 evaluable patients in an expansion of the company's phase 1b study of botensilimab (multifunctional ctla-4 antibody) in combination with balstilimab (pd-1 antibody) in patients with recurrent platinum resistant/refractory ovarian cancer.
AGEN Ratings Summary
AGEN Quant Ranking